Navigation Links
Paragon Bioservices Wins CMO Leadership Awards for Third Consecutive Year
Date:9/10/2013

BALTIMORE, Sept. 10, 2013 /PRNewswire/ -- Paragon Bioservices, a contract manufacturing organization whose expertise is the process development and manufacturing of biopharmaceuticals, announced today that it has been awarded the 2013 CMO Leadership Award for Quality and Reliability.

"We are very honored to receive this award from Life Science Leader -- especially because this is our third consecutive year," said Dr Marco Chacon, Paragon's CEO. "For more than twenty years, we have helped pharmaceutical and biotechnology companies and government agencies move forward in the development and manufacturing of vaccines (VLPs), monoclonal antibodies and therapeutic proteins.  We've completed two expansions in the past 4 years in order to constantly improve these capabilities.  Therefore, customer service, quality and reliability truly are key areas of focus at Paragon Bioservices.  The fact that we were recognized in the top 20% by more than 10,000 pharmaceutical executives is extremely gratifying to all of us at Paragon."

According to Jon Howland, Vice President of Publishing at Life Science Leader magazine, "These awards were conceived to better serve pharmaceutical and biopharmaceutical executives in their vetting process.  It gives them information on what their peers think of a wide range of CMOs and helps them to ultimately identify the leading CMOs in the industry."

ABOUT PARAGON BIOSERVICES, INC.
Paragon is a Contract Research & GMP Manufacturing Organization (CMO) delivering research, process development and manufacturing services. Paragon's focus is biopharmaceuticals -- including recombinant proteins, viral vectors, vaccines, VLPs, and bacteriophage. Our clients include pharmaceutical companies, biotechnology companies and federal agencies.  Our GMP space includes microbial and mammalian suites, fill-finish, and full
'/>"/>

SOURCE Paragon Bioservices, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Bausch + Lomb Signs Exclusive License Agreement with Paragon BioTeck for Phenylephrine
2. Biotechnology Market (Biopharmacy, Bioservices, Bioagri, Bioindustrial) Is Expected to Reach USD 414.5 Billion Globally in 2017: Transparency Market Research
3. Fisher BioServices Intensifies Commitment for Cell Therapy Companies in Clinical Trials and Approaching Commercialization
4. Nabsys Expands Leadership Team to Prepare for Commercialization of Novel DNA Positional Sequencing Technology
5. Berkeley Lab seeks to help US assert scientific leadership in critical materials
6. Auxilium Announces Appointments to Enhance Leadership Team
7. More than half of Americans doubt US global leadership in 2020
8. USC Marshall School of Business 6th Annual Leadership Summit
9. Oncobiologics Fills Key Leadership Positions and Names Scientific Advisory Board
10. BioMotiv Launches Novel Drug Development Operation, Names Leadership Team
11. Innovation Leaders from Across Industries will Convene to Share Best Practices and Breakthrough Successes at Open Innovation Leadership Summit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... THOUSAND OAKS, Calif. , May 27, 2015 /PRNewswire/ ... company, has been awarded a U.S. patent for a ... gene in areas such as research, product development and ... useful in regulating key biosynthetic processes that are the ... to offer other seed companies a commercial license to ...
(Date:5/26/2015)... OTTAWA, Canada, and BELLINGHAM, Washington, USA (PRWEB) May 26, ... has signed a formal partnership with the ... Ottawa Centre for Extreme and Quantum Photonics. The center ... in the field of photonics, and will be only ... Arthurs, CEO of SPIE, the international society for ...
(Date:5/26/2015)... and HILDEN, Germany , May ... (NASDAQ: QGEN ; Frankfurt Prime Standard: QIA) ... Clinical Insight ® (QCI™) bioinformatics content and ... and report on genomic variants identified in next-generation ... the bioinformatics platform are in oncology, for somatic ...
(Date:5/26/2015)... (PRWEB) May 26, 2015 Global ... have announced plans for the company’s first cellular and ... followed by a full day, hands-on stem cell training ... J. Victor Garcia Gimenez, M.D., President of Therapeutic Confrontations ... medical community’s increasing interest in regenerative medicine and recent ...
Breaking Biology Technology:Ceres Awarded Patent for Innovation in Soybean 2Ceres Awarded Patent for Innovation in Soybean 3Third Max Planck Centre in North America Inaugurated at University of Ottawa 2Third Max Planck Centre in North America Inaugurated at University of Ottawa 3QIAGEN Launches Clinical Bioinformatics Platform for Next-Generation Sequencing 2QIAGEN Launches Clinical Bioinformatics Platform for Next-Generation Sequencing 3QIAGEN Launches Clinical Bioinformatics Platform for Next-Generation Sequencing 4QIAGEN Launches Clinical Bioinformatics Platform for Next-Generation Sequencing 5Stem Cell Training, Inc. Announces First European Symposium on Cellular and Regenerative Medicine 2Stem Cell Training, Inc. Announces First European Symposium on Cellular and Regenerative Medicine 3
... Adult Cough Products Using ... Technologies, CHESTER, N.J. and SALT LAKE CITY, Sept. ... and Lipocine Inc., a,privately- held, leading drug delivery company ... drug delivery and,therapeutics needs, today announced that they have ...
... Company Enters Into License, Commercialization and Supply Agreement, Company to Host Conference ... ... 2007, LEXINGTON, Mass., Sept. 19 ... AGN ), through its acquisition of Esprit Pharma, has obtained the,United States ...
... Kleiner Perkins ... Strong Endorsement of Technology Pioneer at Forefront of Developing No- ... Compromise Biofuels, ... hydrocarbon biofuels, today,announced that it closed the first tranche of its $70 million ...
Cached Biology Technology:Adams Respiratory Therapeutics and Lipocine Enter into License and Collaboration Agreement 2Adams Respiratory Therapeutics and Lipocine Enter into License and Collaboration Agreement 3Indevus Announces Allergan as New Partner for SANCTURA Brand 2Indevus Announces Allergan as New Partner for SANCTURA Brand 3Indevus Announces Allergan as New Partner for SANCTURA Brand 4Indevus Announces Allergan as New Partner for SANCTURA Brand 5Indevus Announces Allergan as New Partner for SANCTURA Brand 6Amyris Biotechnologies Announces $70 Million Series B Round 2
(Date:5/11/2015)... , May 11, 2015 Curemark LLC, ... the start of a new Phase III double blind, ... its novel formulation, CM-AT, on all children ages 3-8 ... its FDA Phase III double blinded clinical trial for ... low levels of the digestive enzyme chymotrypsin. This new ...
(Date:5/5/2015)... , May 5, 2015, NXT-ID, Inc. (NASDAQ: ... focused on the growing mobile commerce market, reminds investors and ... Technology Officer, is presenting  at CARTES SECURE CONNEXIONS AMERICA 2015, ... 2015. The three-day conference is organized into ... speaking in is themed Global Fraud: Where is the ...
(Date:4/20/2015)... Calif. , April 20, 2015 Huntington ... Gabriel Valley to implant a new miniaturized, wireless monitoring ... System is the first and only FDA-approved heart failure ... hospital admissions when used by physicians to manage heart ... sensor that is implanted in the pulmonary artery (PA) ...
Breaking Biology News(10 mins):Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3
... therapy often harms healthy tissue as it tries to kill ... Department of Biomedical Engineering is developing a new way to ... surrounding tissue. His innovative method, soon to be ... kill the tumor cells but leaves surrounding healthy tissue intact. ...
... a leading cause of mortality worldwide, accounting for more than ... expected to exceed 12 million. The ESMO Congress provides a ... the treatment of cancer Congress Program Highlights ... potentially practice changing, Promising new drugs to treat ovarian, skin, ...
... Under the microscope, the bacteria start dividing normally, two ... then individual cells begin "popping," like circus balloons being struck ... bioengineers who captured it on video, turns out to be ... considered by scientists creating living, synthetic circuits out of bacteria. ...
Cached Biology News:A 'magnetic' solution to identify and kill tumors 235th ESMO Congress media alert 235th ESMO Congress media alert 3Popping cells surprise living circuits creators 2Popping cells surprise living circuits creators 3
Antibodies were affinity purified using epitopes specific to JLP immobilized on solid support....
... N.C. Price (1996) • This ... protein chemistry and the purification ... Data on the following procedures ... determination, amino acid analysis and ...
... Dunbar (1994) • This book describes ... methods for preparing samples for protein ... radiometric and bioluminescence-enhanced detection systems are ... the detection and characterization of glycoprotein ...
See product name for description....
Biology Products: